َabout Dr

مکان شما: / َabout Dr

  • Dr.Hamidreza Dehghan Manshadi

    Radiation Oncologist

2008                                       Fellowship in Brachytherapy,

                                               European Society for Radiation-oncology, Belgium

 

2002- 2005                            Specialized Board in Radiation-oncology,

                                               Tehran University of Medical Sciences (TUMS), Iran 

 

1988-1995                             Medicine,

                                               Shahid Beheshti University of Medical Sciences (SBMU), Iran 

2011-Present        Managing Director at Baran clinic

 

2011-2013             Scientific Representative of Electa-Neucleotron in Middle East

 

2009-Present        Head of Clinical Radiation-oncology Department

                              7-Tir Hospital, Tehran, Iran

 

2007-Present       Establishment of the first specialized brachytherapy center at Atieh

                             hospital as an educational and therapeutic center for women cancers,

                             sarcoma, rectum and prostate cancers

 

2007-Present       Cooperation in establishment of radiotherapy center at Pars hospital that

                             is equipped with linear accelerator including conformal equipments as the

                             first non-governmental radiotherapy center in Tehran

 

 

1995-1997            Special Medical Center Representative, Tafresh, Iran

 

  • Pharmacogenetics of Breast cancer among Iranian population (ongoing)

 

  • Identification of molecular markers for cancer susceptibility among Iranian

        Population (ongoing)

 

  • Outcomes of survival of High-Dose-Rate Brachytherapy (Iridium-192) in the

        treatment of recurrent Malignant Gliomas in Shohada-Tajrish Hospital (2011)

  • Study of Tissue Inconsistency on Distribution and SAVI Applicator Dose in Breast Brachytherapy Using Monte Carlo Method (Islamic Azad University, 2016)
  • Pharmacogenetics of Cyclophosphamide in Breast Cancer Patients (National Institute of Genetic Engineering and Biotechnology, 2015)
  • Pharmacogenetics of Doxorubicin in Breast Cancer Patients (National Institute of Genetic Engineering and Biotechnology, 2015)
  • Providing a Model for Correction of Cervix Cancer Brachytherapy Design Based on Anatomic Alterations, (Shahid Beheshti University of Medical Sciences. 2014)
  • Evaluation of accuracy of the delivered dose to rectum in HDR brachytherapy in treatment of endometrial and cervix cancers using Flexiplan 3D treatment program (Tehran Uinversity of Medical Sciences, 2010) 
  • Study of Major Stress on Emerging of Breast Cancer in 20-50 Years old Women (Iran University of Medical Sciences, 2008)

2011-2013                          Scientific Representative of Electa-Neucleotron in Middle East

2012                                   Brachytherapy Educational Course, Pakistan

2011-2013                          Oncology Course for Intern Students of Shahid Beheshti                                                     University

2017                  European Cancer Summit, Italy

2016                  ESMO Asia, Singapore

2016                  ESTRO 35 Congress, Italy

2015                  ESMO Asia, Singapore

2014                  EMS Scientific Exchange Meeting Gastric and Thoracic Cancer, UAE

2014                  ESTRO 33 Congress, Austria

2013                  2nd ESTRO Forum, Switzerland

2013                  Brachytherapy Middle East User Group Meeting, UAE

2012                  Chief Member of Brachytherapy Conference, UAE

2012                  3rd Asian Breast Cancer Congress, India

2012                  International Multidiciplinary Cancer Congress, Iran

2012                  4th National Congress of Iranian Society of Gynaecology-oncology, Iran

2011                  13th World Congress on Gastrointestinal Cancer, Spain

2010                  3rd Congress of Iranian Society of Women Cancers, Iran

2010                  3D Image-Based Brachytherapy in Gynaecological Malignancies, Poland

2009                   4th Best of ASCO Congress, Lebanon

2009                  Continued Training Programs in Chemotherapy, Iran

2009                   Continued Training Programs in Trophoblastic Diseases, Iran

2009                  International Congress of Iranian Society of Women Cancers, Iran

2008                   Continued Training Programs in Radiotherapy and Chemotherapy for

                           Treatment of Cervix Cancer and its recurrence, Iran

2008                   Continued Training Programs in Cervix Cancer and Pre-cancer lesions,

                           Iran

2006                   Conference on Soft Tissue Sacrum News, Iran

2006                   Annual Congress of Iranian Society of Pathology, Iran

2006                   Conference on the Role of the Endocrine Therapy in Breast Cancer, Iran

2005                   Conference on Gastrointestinal Cancers, Iran  

2005                   The First national Congress on Gyncology-oncology, Iran

2005                   Monthly Conference of Iranian Society of Women Cancers, Iran

2001                   12th European Students Conference for Medical Students, Germany

1.    M. Mobaraki, A. Faraji, M. Zare, P. Dolati, M. Ataei and H. R. Dehghan Manshadi*. Molecular Mechanisms of Cardiotoxicity: A Review on Major Side-effect of Doxorubicin. Indian Journal of Pharmaceutical Sciences 2017; 79(3):335

 

  • Abolfazl Faraji, Hamid Reza Dehghan Manshadi*, Maryam Mobaraki, Mahkameh Zare, Massoud Houshmand*. Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. PLoS ONE 2016; 11(12):e0168519.

  • M. Mobaraki, H. R. Dehghan Manshadi, A. Faraji, M. Zare, M. H. Sanati*. Impact of GSTP1 and ABCC4 Genes Polymorphism on Outbreak of Cyclophosphamide-based Chemotherapy-induced Grade 3/4 Febrile Neutropenia in Iranian Breast Cancer Patients. Annals of Oncology 2016; 27(Supp 9):39P.

    •  

  • Abolfazl Faraji, Hamid Reza Dehghan Manshadi*, Maryam Mobaraki, Mahkameh Zare, Massoud Houshmand*. Effect of ABCB1 and SLC22A16 genes polymorphism in outbreak of doxorubicin-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian breast cancer patients. Annals of Oncology 2016; 27(Supp 9):40P.

    •  

  • M. Zare, M. Aghili, B. Kalaghchi, H. Dehghan Manshadi, E. Esmati. Efficacy of gabapentin for prevention of paclitaxel induced neuropathy: randomized double blind, phase 3 trial. Annals of Oncology 2016; 27(Supp 9):91P.

  • M. Mobaraki, H. R. Dehghan Manshadi, A. Faraji, M. Zare, M. H. Sanati*. The Association of Polymorphism in GSTP1 and ABCC4 Genes with the Cyclophosphamide-induced Neutropenia in Iranian Breast Cancer Patients. Under review at Pharmacogenomics, 2016

    • 7.    Zahra Siavashpour, Mahmoud Reza Aghamiri, Ramin Jaberi, Hamid Reza Dehghan Manshadi, Reza Ghaderi, Christian Kirisits. Optimum organ volume ranges for organs at risk dose in cervical cancer intracavitary brachytherapy. J Contemp Brachytherapy 2016; 8(2):135–142.

     

    8.    Zahra Siavashpour, Mahmoud Reza Aghamiri, Ramin Jaberi, Naser ZareAkha, Hamid Reza Dehghan Manshadi, Christian Kirisits, Mahbod Sedaghat. A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes. JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 17, NUMBER 3, 2016.

    9.    Zahra Siavashpour*, Mahmoud Reza Aghamiri, Ramin Jaberi, Hamid Reza DehghanManshadi, MahbodSedaghat, Christian Kirisits. Evaluating the utility of ‘‘3D Slicer’’ as a fast and independent tool to assess intrafractional organ dose variations in gynecological brachytherapy. Brachytherapy, 2016.

    10. Hamid Reza Dehghan Manshadi, Marzieh Lashkari, Mahkameh Zare, Ramin Jaberi, Rubik Behbo, Ehsan Karbasi. High-Dose-Rate brachytherapy (HDR-BT) with neoadjuvant chemoradiation for advanced rectal cancer. IMJ-Health 2016; 2 (3).

    1. PO-1010: Siavashpour, M.R. Aghamiri, R. Jaberi, N. ZareAkha, H.R. Dehghan Manshadi. Full or empty bladder preference, from this OAR dose viewpoint, in different Tandem length ICBT applicator insertion. Radiotherapy and Oncology, 2014, Volume 111 , S148 – S149.

     

    1. PO-0960: Siavashpour, M.R. Aghamiri, R. Jaberi, N. Zare Akha, H.R. Dehghan Manshadi, S. Karimkhani Zand. Effect of bladder fullness in brachytherapy procedure for EBRT complete response treated cervical cancer patients. Radiotherapy and Oncology, 2013, Volume 106, S370.
    1. Hariri, M. R. Aghamiri, S. Najarian, R. Jaberi, M. Azmi, H. R. Dehghan, S. Hajizadeh. Endoscopic Guided Brachytherapy in Gastric Cancer. World Congress on Medical Physics and Biomedical Engineering, 2009, Volume 25, pp 220-223.
    1. PO55: Sanaz Hariri, Mahmood Reza Aghamiri, Siamak Najarian, Ramin Jaberi, Mehrdad Azmi, Hamid Reza Dehghan, Siamak Hajizadeh. A novel approach to manage gastric adenocarcinoma. Brachytherapy, 2009, Volume 8, Issue 2, 158-159.

     

    1. Samiee, MD H.R. Dehghan Manshadi*, MD R. Jaberi, MS, A.A. Sharafi, PhD A.P. Meysami, MD, MPH . Gharaati, PhD. Rectal Dose Evaluation and Comparison between In-Vivo & Planning Dosimetry in Patients with Cervical & Endometrial Cancer who Received Brachytherapy Treatment. Razi Journal of Medical Sciences RJMS, 2006, 12(49): 89-96

     

    1. Zahar Siavashpour, Mahmoud Reza Aghamiri, Ramin Jaberi, Hamid Reza Dehghan Manshadi, Naser ZareAkha, Mozafar Darvishi, Christian Kirisits. Evaluation of organ at risks received dose based on organ volume status in 3D GYN intracavitary brachytherapy according to the GEC-ESTRO recommendation on contouring and dose constrains. Submitted to Japanees journal of radiology